Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2024-07-24 Earnings Release
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
CS - Importanti Risultati di Vendita e Posizionamento sul Mercato Nutraceutico Italiano
Earnings Release Classification · 1% confidence The document is a formal communication titled 'Informazione Regolamentata' (Regulated Information) from PHARMANUTRA S.P.A. The subject is 'CS - Importanti Risultati di Vendita e Posizionamento sul Mercato Nutraceutico Italiano' (Important Sales Results and Positioning in the Italian Nutraceutical Market). It details strong sales performance based on IQVIA sell-out data, showing growth rates and market ranking improvements up to 2023 and H1 2024. This content is a press release announcing key financial/operational highlights for a specific period, rather than the full, comprehensive annual report (10-K) or a detailed interim report (IR). It fits the definition of an initial announcement of periodical financial results/key highlights. It is not a Call Transcript (CT), Audit Report (AR), or a mere announcement of a report publication (RPA), as it contains the substantive results itself. Therefore, it is classified as an Earnings Release (ER). H1 2024
2024-07-24 Italian
COMUNICAZIONE INTERNAL DEALING
Director's Dealing Classification · 1% confidence The document text explicitly contains the subject line: 'Oggetto: COMUNICAZIONE INTERNAL DEALING' and the title 'Modello di notifica e di comunicazione al pubblico delle operazioni effettuate da persone che esercitano funzioni di amministrazione, di controllo o di direzione e da persone a loro strettamente associate.' This structure and content directly correspond to the reporting requirements for insider transactions, which aligns with the definition for Director's Dealing (DIRS). Although the document is short and references an attachment ('Vedi allegato'), the core content is the notification template itself, making it a specific regulatory disclosure rather than a general announcement of a report (RPA/RNS).
2024-07-23 Italian
Allegato 3F | Giugno 2024
Transaction in Own Shares Classification · 1% confidence The document is titled 'SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE' (Model Disclosure for Transactions in the Issuer's Securities) and specifically details transactions (purchases and sales) in the issuer's shares (Pharmanutra S.p.A.) conducted by a third party (INTERMONTE SPA) during June 2024. Section 2 details daily transactions, and Section 3 discusses the status of the share repurchase/sale program. This content directly corresponds to the definition of reporting transactions in own shares, which is classified as 'Transaction in Own Shares' (POS). Although the transactions might be related to a buyback program, the core disclosure format is for reporting these specific transactions.
2024-07-05 Italian
PR_Effectiveness of the merger by incorporation
AGM Information Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated July 5, 2024, announcing that the 'merger by incorporation' of two subsidiaries became effective on July 4, 2024. This type of corporate restructuring, involving mergers and acquisitions, falls under the category of M&A activity. The filing type code corresponding to Merger Proposals or Takeover Bids is TAR (M&A Activity). Although it is a formal announcement, the core subject matter is the completion of a significant corporate transaction (merger), making TAR more specific than a general RPA or RNS.
2024-07-05 English
CS_Pharmanutra efficacia della fusione
M&A Activity Classification · 1% confidence The document is an official communication ('Informazione Regolamentata') from Pharmanutra S.p.A. dated July 5, 2024. The subject ('Oggetto') is 'CS_Pharmanutra efficacia della fusione' (Effectiveness of the merger). The text explicitly announces that the merger by incorporation of Junia Pharma S.r.l. and Alesco S.r.l. into Pharmanutra S.p.A. became effective on July 4, 2024. This type of announcement, detailing a significant corporate restructuring event like a merger, falls under corporate actions related to capital structure or major transactions. Since there is no specific code for 'Merger Announcement,' the closest fit among the provided options that covers significant corporate/financing changes is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a standard regulatory filing (RNS) as it details a specific, major corporate event outcome. Given the focus on the completion of a merger, CAP is the most appropriate classification.
2024-07-05 Italian
COMUNICAZIONE INTERNAL DEALING
Director's Dealing Classification · 1% confidence The document is titled 'Modello di notifica e di comunicazione al pubblico delle operazioni effettuate da persone che esercitano funzioni di amministrazione, di controllo o di direzione e da persone a loro strettamente associate' (Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them). The 'Oggetto' (Subject) is 'COMUNICAZIONE INTERNAL DEALING'. This clearly indicates a report concerning insider trading or director/executive transactions. This aligns directly with the definition for Director's Dealing (DIRS). Although the text states 'Vedi allegato' (See attachment), the document itself is the formal notification structure, not just an announcement of a future report, and it contains the core details of the transaction notification.
2024-06-22 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.